Trial Profile
A Prospective, Open-label Multicentre Real-word Study of Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy as Neoadjuvant Therapy for Women With HER2-positive and p95HER2-positive PI3K Mutation or PTEN Loss Breast Cancer
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Lapatinib (Primary) ; Cyclophosphamide; Epirubicin; Paclitaxel; Trastuzumab
- Indications Advanced breast cancer; Early breast cancer
- Focus Therapeutic Use
- 08 Sep 2017 New trial record